Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions and methods for metabolic modulation

Inactive Publication Date: 2007-07-12
VDF FUTURECEUTICALS
View PDF2 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] Thus, while numerous compositions and methods for metabolic control are known in the art, all or almost all of them, suffer from one or more disadvantages. Similarly, numerous uses for cytokinins are known in the art. However, none of th

Problems solved by technology

Pre-diabetes, insulin resistance, type-2 diabetes (non-insulin dependent diabetes, NIDDM), syndrome X, and dyslipidemia pose a substantial health threat to a significant portion of the population in the US and other industrialized nations.
Unfortunately, many biguanides also produce lactic acidosis, which may become a life-threatening condition, especially where a patient has renal insufficiency.
Still further, biguanide therapy is often counter-indicated where a patient takes other drugs that interfere with renal function.
However, various glitazones have been withdrawn from the market or development has discontinued due to relatively high hepatotoxicity.
Moreover, numerous other side effects include weight gain and fluid retention.
Worse yet, tolbutamide (a sulfonylurea) was shown to increase the risk of cardiovascular mortality, which may also be the case in other sulfonylureas and meglitinides due to their common mode of action.
However, while some disadvantages may be mitigated, other disadvantages nevertheless remain.
There are numerous insulin formulations known in the art (e.g., fast acting, intermediate acting, long acting), and depending on the type of insulin, problems may arise with immunogenicity, tolerability, and / or long-term effectiveness.
Furthermore, correct administration of such preparations must be verified via blood tests that add to the inconvenience of such therapy.
However, at least some of these nutritional supplements exhibit significant toxicity (e.g., Cr-picolinate), and / or the chromium has only relatively low solubility and / or bioavailability.
However, to achieve substantial normalizing effect, at least some forms of such products need to be ingested at rather large amounts.
However, such claims are typically not verified or endorsed by the FDA, and the efficacy for the advertised purpose is questionable for all or almost all of these supplements.
Thus, while numerous compositions and methods for metabolic control are known in the art, all or almost all of them, suffer from one or more disadvantages.
However, none of the known methods teaches or suggests use of cytokinins for specific metabolic modulation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions and methods for metabolic modulation
  • Pharmaceutical compositions and methods for metabolic modulation
  • Pharmaceutical compositions and methods for metabolic modulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] The inventors have unexpectedly discovered that numerous cytokinins and cytokinin glycosides have various desirable biological properties in mammals that heretofore have not been recognized.

[0033] More specifically, and in one aspect of the inventive subject matter, contemplated compositions and methods have been proven effective to treat at least one of pre-diabetes, insulin resistance, type-2 diabetes, syndrome X, and dyslipidemia in human. While not limiting to the inventive subject matter, the inventors contemplate that such effects may be due to activation of GLUT4, AMPK, and / or Akt, and reduction in activity of ACC and / or HMGCoA reductase.

Definition of Terms

[0034] The term “cytokinin” as used herein refers to a variety of compounds with biological activity, and especially cytokinin activity. Particularly contemplated cytokinins include those having a purine scaffold, and even more preferably those having an N6-substituted adenine scaffold. However, it should be reco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Electrical resistanceaaaaaaaaaa
Login to View More

Abstract

Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and / or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and / or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and / or Akt. Consequently, various diseases associated with dysregulation of AMPK and / or Akt may be treated using the compounds of the present inventive subject matter.

Description

[0001] This application claims the benefit of U.S. Provisional Patent Applications Ser. Nos. 60 / 493,447; 60 / 499,637; 60 / 511,746; 60 / 562,384; and 60 / 562,496; which were filed Aug. 8, 2003; Sep. 2, 2003; Oct. 15, 2003; Apr. 14, 2004; and Apr. 14, 2004; respectively, all of which are incorporated by reference herein.FIELD OF THE INVENTION [0002] The field of the invention is pharmaceutical compositions and methods for metabolic modulation. BACKGROUND OF THE INVENTION [0003] Pre-diabetes, insulin resistance, type-2 diabetes (non-insulin dependent diabetes, NIDDM), syndrome X, and dyslipidemia pose a substantial health threat to a significant portion of the population in the US and other industrialized nations. [0004] For example, about 6.3% of all US citizens are diagnosed with diabetes, and another 5.2 million people are suspected to be undiagnosed (National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2003. Rev ed. Atlanta, Ga.: U.S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7076A61K31/7052A61K31/52A61KA61K48/00
CPCA61K31/513A61K31/52G01N2800/044G01N2800/042G01N33/74A61K45/06A61K31/7076A61K31/522A61K31/7052A61K2300/00A61P3/00
Inventor MIJIKOVIC, DUSANHRANISAVLJEVIC, JOVANPIETRZKOWSKI, ZBIGNIEW
Owner VDF FUTURECEUTICALS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products